CDC panel recommends AZ's FluMist for 2018-19 season

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 12-2 in favor of recommending FluMist Quadrivalent from AstraZeneca plc (LSE:AZN; NYSE:AZN) as an age-appropriate option for flu prevention for the 2018-2019 influenza season, according to CDC spokesperson Kristen Nordlund.

CDC recommended against the intranasal live attenuated influenza vaccine (LAIV) for the current season, citing efficacy concerns against a specific strain of influenza A (H1N1) in the 2013-14 and 2015-16 flu seasons. FluMist Quadrivalent contains two strains of type A (H1N1 and H3N2) and two strains of type B (one each from Yamagata and Victoria lineages)...